Processing timeline
1
days
Filed
27 July 2026
Decision Due
7 Sept 2026
Est decision date: 27 Aug 2026. Based on 53 decided Professional & Business Services notifications.
Acquirer(s)
AbbVie Inc. DELAWARE FILE NO. - 5126809, Andor Merger Co. DELAWARE FILE NO. - 10659205, Andor LLC DELAWARE FILE NO. - 10659200
Target(s) or Vendor(s)
Apogee Therapeutics, Inc. EIN - 934958665, Apogee Therapeutics Securities Corporation EIN - 33-2083626
Other parties
None listed
AbbVie Inc., a global biopharmaceutical company, proposes to acquire all outstanding shares of Apogee Therapeutics, Inc., a clinical-stage biotechnology company. This share acquisition involves an overlap in the development of therapies for atopic dermatitis, a key area for both companies within the biopharmaceutical industry.
AbbVie Inc. ( AbbVie ) proposes to acquire all of the outstanding shares of Apogee Therapeutics, Inc. ( Apogee ) (the Acquisition ). AbbVie is a North Chicago-based, New York Stock Exchange-listed global biopharmaceutical company active in the development and supply of medicines and therapies across a range of therapeutic areas, including immunology, oncology, neuroscience, aesthetics and eye care. In Australia, AbbVie supplies Rinvoq, a Janus Kinase ( JAK ) inhibitor used to treat atopic dermatitis. Apogee is a San Francisco-based, NASDAQ-listed clinical-stage biotechnology company focused on developing a pipeline of biologic therapies for inflammatory and immunological diseases, including atopic dermatitis, asthma, eosinophilic oesophagitis and chronic obstructive pulmonary disease. Apogee’s lead asset, zumilokibart (APG777), is a clinical-stage (Phase 2b) monoclonal antibody therapy that targets interleukin-13 (IL-13) for the treatment of atopic dermatitis. Apogee does not have any marketed products anywhere in the world. AbbVie and Apogee overlap in the development of therapies for the treatment of atopic dermatitis.
The ACCC has prepared a questionnaire on the Acquisition. Submissions or information in response to the questionnaire should be provided by 04 August 2026 via email to mergers@accc.gov.au with the title Submission re: AbbVie - Apogee. The ACCC’s ability to give detailed consideration to submissions received after this time may be limited.